Search

AZD-8330

AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. … AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.

4-nitrophenyl-beta-D-galactoside

Sucralose

Sucralose is an artificial sweetener used as a sugar substitute.

Anumigilimab

CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. … [A225626] It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.[L27516]

Ordopidine

ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses. … ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects

Flutemetamol

Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).

Polaprezinc

Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856].

4-Hydroxytestosterone

It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … It is specifically the 17-hydroxylated analog to formestane.

GT 389-255

MAD) Phase I trials. … It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.

XL281

XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. … XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway.